TITLE

LINUX NETWORX CLUSTER SPEEDS DEVELOPMENT OF DIAGNOSTICS

PUB. DATE
July 2003
SOURCE
UNIX Update;Jul2003, Vol. 14 Issue 7, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that DiaDexus, a developer of diagnostic and therapeutic products, is using Linux Networx Evolocity II cluster computing system to expedite the development of diagnostic products for cancer and cardiovascular disease.
ACCESSION #
10161541

 

Related Articles

  • Automated version of diaDexus'.  // Cardiovascular Devices & Drugs;Feb2008, Vol. 14 Issue 2, p15 

    The article announces that diaDexus has received clearance from the U.S. Food and Drug Administration for a new automated version of its PLAC Test, which measures lipoprotein-associated phospholipase A2.

  • Corgenix in management, supply pact with diaDexus.  // Medical Device Daily;6/20/2012, Vol. 16 Issue 117, p3 

    The article reports that diagnostic test kit developer Corgenix Medical, along with its subsidiary, Corgenix, has signed a contract manufacturing and supply deal with diaDexus, a company that develops and commercializes proprietary cardiovascular diagnostic products.

  • VaxGen now renamed diaDexus.  // Medical Device Daily;11/5/2010, Vol. 14 Issue 216, p5 

    The article reports on the name change of VaxGen, a diagnostics company focused on in vitro diagnostic products addressing unmet needs in cardiovascular disease, to diaDexus in November 2010.

  • diDexus launches Plac test.  // Medical Device Daily;3/6/2012, Vol. 16 Issue 44, p10 

    The article features the Plac Test for Lp-LPA(2) Activity from diaDexus.

  • Identity risk.  // MLO: Medical Laboratory Observer;Jun2008, Vol. 40 Issue 6, p48 

    The article evaluates the PLAC test reagents from diaDexus Inc.

  • Deals roundup.  // Medical Device Daily;7/30/2010, Vol. 14 Issue 147, p2 

    This article focuses on the merger deal completed by VaxGen with diaDexus, a diagnostic firm focused on in vitro diagnostic products.

  • Medarex and diaDexus to develop cancer antibodies.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p14 

    Announces the expansion of the existing collaboration of Medarex and diaDexus for the research and development of fully human antibody therapeutics against novel cancer targets provided by diaDexus. Plan of the companies to share the cost of development and commercialization as well as potential...

  • Stock Movers.  // BioWorld Today;7/26/2013, Vol. 24 Issue 142, p2 

    A chart is presented that shows the trends and values of stocks of several international biotechnology companies including Diadexus Inc., Intermune Inc. and Aeterna Zentaris Inc.

  • R&D UPDATE - Key Announcements.  // PharmaWatch: Cancer;March 2003, Vol. 2 Issue 3, p2 

    Announces updates on cancer drug development worldwide as of February 2003. Grant awarded to American Pharmaceutical Partners Inc. by the U.S. Food and Drug Administration; Cooperation between Medarex Inc. and diaDexus Inc. for the development of human antibody therapeutics; Benefits of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics